{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.6","upperLimit":"67.0","value":"3.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Time from date of treatment start until the date of first objective documentation of disease-relapse.","dispersionType":"Full Range","groups":[{"description":"Patients receive DA-EPOCH regimen comprising doxorubicin hydrochloride IV, vincristine sulfate IV, and etoposide IV continuously over 96 hours on days 1-4; cyclophosphamide IV over 1-2 hours on day 5; and prednisone PO BID on days 1-5. Patients also receive ofatumumab IV over 2 hours on days 1, 2, and 11 of cycle 1; on days 1 and 8 of cycles 2 and 4; and on days 1 and 11 of cycle 3 for a total of 9 injections. Patients may receive rituximab instead of ofatumumab if their insurance provider does not cover the cost of ofatumumab. Patients receive rituximab IV over 2 hours on days 1 and 11 of cycles 1 and 3 and on days 2 and 8 of cycles 2 and 4. Treatment repeats every 21-28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.\n\nCyclophosphamide: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nEtoposide: Given IV\n\nOfatumumab: Given IV\n\nPrednisone: Given PO\n\nRituximab: Given IV\n\nVincristine Sulfate: Given IV","id":"OG000","title":"Treatment (DA-EPOCH and Ofatumumab or Rituximab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 8 years","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}